The 3C-HF score stratifies the individual patient mortality risk at one year, a time-span that is critical for treatment choices, such as device therapy, but still minimizes the potentially larger impact of comorbidities, rather than cardiac conditions, on outcome.
Risk stratification should be repeated after one year, or in case of any significant change in the considered variables.
